GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Oramed Pharmaceuticals (Oramed Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.


Oramed Pharmaceuticals  (NAS:ORMP) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Oramed Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Comparable Companies
AFMD MIRO ATHA MDWD EYEN IKNA IFRX SGMO RLYB JSPR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
OJU1:Germany
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Website
https://www.oramed.com
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Executives
Benjamin Shapiro director 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron director, 10 percent owner 142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov director 9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron director 2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz officer: Chief Commercial Officer 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer director MORAN 16, KFAR SABA L3 4428890
Netanel Derovan officer: Chief Legal Officer 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman officer: Chief Financial Officer 20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin director 36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz officer: Chief Commercial Officer MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank director 3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming director 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay officer: CFO, Treasurer and Secretary 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton officer: VP Business Development 13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman director HADASSA 6, TEL AVIV L3 6451306